10-Q quarterly report · filed Nov 4, 2026

Innoviva, Inc. (INVA) Q3 2026 10-Q Quarterly Report

Short answer

Innoviva, Inc. (INVA) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $106M (down 1.6% year over year) with net income of −$74M.

Q3 2026 key financials · XBRL

Revenue
$106M
−1.6% YoY · −11.3% QoQ
Net income
−$74M
−182.2% YoY · +11.4% QoQ
Operating margin
39.7%
Gross margin
79.5%
EPS (diluted)
−$0.85
−176.6% YoY · +12.4% QoQ

Source: XBRL data from the Innoviva, Inc. (INVA) Q3 2026 10-Q on SEC EDGAR. USD.

Innoviva, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $106.1M, down 1.6% YoY from $107.8M, with net product sales $49.4M
  • Operating income $42.2M, up 21.9% YoY from $34.6M
  • Best performer: U.S. XACDURO sales $16.1M, up $7.6M YoY; worst: ex-U.S. XERAVA sales $1.7M, down 91%
  • Cash $581.4M; operating cash flow $129.0M vs $142.4M YoY; share repurchases $26.3M
  • Near-term outlook: cash sufficient for at least 12 months; NUZOLVENCE commercialization focused on market access and distribution infrastructure

Risk Factors

  • No material changes to 2025 Form 10-K risk factors
  • Carried-forward risks remain the company’s primary disclosed exposures
  • No new regulatory, legal, or compliance risk identified
  • No new operational, competitive, or market risk identified
  • No new liquidity, debt, currency, or concentration risk identified

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Innoviva, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.